Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 17 April 2026Expected publication date: 7 May 2026